1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Zur Rose Group AG
  6. News
  7. Summary
    ROSE   CH0042615283

ZUR ROSE GROUP AG

(ROSE)
  Report
Delayed Swiss Exchange  -  11:31 2022-07-05 am EDT
76.00 CHF   +3.26%
06/30ZUR ROSE GROUP : Barclays gives a Buy rating
MD
06/22ZUR ROSE : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
PU
06/22ZUR ROSE GROUP : Credit Suisse reaffirms its Sell rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Zur Rose : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH

06/22/2022 | 10:55am EDT

Berlin, 22.06.2022- The CEO and co-founder of eHealth-Tec GmbH Tobias Leipold is leaving the subsidiary of the Swiss Zur Rose Group at his own request on 30.06.2022. He would like to devote himself to new challenges in the start-up environment.

Tobias Leipold has led eHealth-Tec GmbH since 2015, building it into one of the most innovative medium-sized companies and successfully integrating it into the Zur Rose Group in 2019. The Berlin-based technology hub is a leader in the digital transformation of the German healthcare system, including as a technical partner in the e-prescription pilot project of Techniker Krankenkasse and with IBM in the development of gematik's e-prescription specialist service.

Madhu Nutakki, Chief Technology Officer of the Zur Rose Group, thanks Tobias Leipold for his high level of personal commitment and entrepreneurial achievement. "Tobias Leipold has succeeded in building eHealth-Tec into a future-oriented technology hub and strengthening the innovative power of the entire Group. He has been instrumental in designing and implementing the e-prescription technology as well as the ERPath emergency room information system. We wish Tobias Leipold all the best for both his professional and private future and every success in his endeavour to bring up-and-coming start-ups to the market." Tobias Leipold will remain available to the Zur Rose Group as an advisor.

The previous co-managing director and Chief Technology Officer of eHealth-Tec, Thomas Rausch, will remain in his current role. The Berlin location will be even more integrated into the Zur Rose Group's tech organisation and further expanded to focus on the key areas of mobile app, web e-commerce and consumer Rx services in addition to its existing capabilities. For the upcoming launch of the electronic prescription, the new capabilities of the Berlin technology hub will be of great benefit. The transformation of the Zur Rose Group into a healthtech provider will thus continue to be consistently driven forward. Madhu Nutakki comments: "Thomas Rausch has profound technology and product expertise. He and his team will develop further digital solutions that are user-friendly and offer real added value."

About eHealth-Tec:
eHealth-Tec (eht) uses structured digital data to develop solutions for networking medical institutions at the highest technical and medical level. The digital medical care process will be fully covered by eht applications: from the doctor to the clinic or pharmacy to other medical stakeholders and patients. The practical relevance and user-friendliness of the innovative software solutions form the basis of eht's work. The vision is to actively shape the digital future of healthcare itself and in many strategic partnerships. eht is already a pioneer in e-prescriptions and emergency room information software. Thanks to its multi-professionalism and many years of experience in the healthcare sector, eht guarantees optimal support for all stakeholders.

Press contact eHealth-Tec:Torben Bonnke
Telephone: +49 30 2122236 12
Mobile: +49 171 864 888 1
Email: presse@ehealth-tec.de

Disclaimer

Zur Rose Group AG published this content on 22 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2022 14:54:04 UTC.


© Publicnow 2022
All news about ZUR ROSE GROUP AG
06/30ZUR ROSE GROUP : Barclays gives a Buy rating
MD
06/22ZUR ROSE : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
PU
06/22ZUR ROSE GROUP : Credit Suisse reaffirms its Sell rating
MD
06/17ZUR ROSE : Tobias Leipold, CEO and Co-Founder, leaves eHealth-Tec GmbH
PU
06/08ZUR ROSE GROUP : Gets a Sell rating from UBS
MD
06/07ZUR ROSE GROUP : Barclays keeps its Buy rating
MD
06/07Aevis Victoria Buys Stake In Swiss Digital Health Platform Well
MT
06/06ZUR ROSE GROUP : Deutsche Bank reaffirms its Buy rating
MD
06/01ZUR ROSE GROUP : Jefferies maintains a Buy rating
MD
06/01ZUR ROSE GROUP : Gets a Buy rating from Barclays
MD
More news
Analyst Recommendations on ZUR ROSE GROUP AG
More recommendations
Financials
Sales 2022 1 772 M 1 828 M 1 828 M
Net income 2022 -166 M -172 M -172 M
Net Debt 2022 437 M 451 M 451 M
P/E ratio 2022 -4,69x
Yield 2022 -
Capitalization 792 M 817 M 817 M
EV / Sales 2022 0,69x
EV / Sales 2023 0,59x
Nbr of Employees 2 131
Free-Float 85,3%
Chart ZUR ROSE GROUP AG
Duration : Period :
Zur Rose Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZUR ROSE GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 76,00 CHF
Average target price 165,92 CHF
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Walter Hess Chief Executive Officer
Marcel Ziwica Chief Financial Officer
Walter Oberhänsli Chairman
Madhu Nutakki Chief Technology Officer
Bernd Michael Gschaider Chief Operating Officer
Sector and Competitors